-
Its estimated that 859 out of 100,000 women of reproductive age receive a cancer diagnosis each year in the United States. Up to 80% of all women diagnosed with cancer prior to age 50 survive at least five years.
-
Results from the 2013 National Youth Risk Behavior Survey indicate that among high school students who are sexually active, condom use has declined from 63% in 2003 to 59% in 2013. This decline follows a period of increased condom use throughout the 1990s and early 2000s.
-
New chlamydia prevalence estimates confirm that young women particularly young African American women continue to bear a disproportionate burden of disease in the United States.
-
Bayer HealthCare Pharmaceuticals has received Food and Drug Administration approval for a new inserter for its Mirena intrauterine contraceptive.
-
A recent study has shown a link between abnormal uterine artery waveforms in the second trimester and reduced fetal movements later in pregnancy, as well as with stillbirth and small for gestational age.
-
Olaparib, a poly (ADP)-ribose polymerase (PARP) inhibitor, demonstrated substantial delay until progression when administered to women as a maintenance therapy with BRCA-mutant recurrent ovarian cancer.
-
Serum anti-Mullerian hormone (AMH) has been well-established as an accurate marker of ovarian reserve. It is solely produced in the human ovary by the granulosa cells.
-
A review of the published literature finds no value to the routine screening pelvic examination in asymptomatic non-pregnant women.
-
-